FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and concerns drug for inhibiting accumulation of liquid into mammals body cavity, having accumulation of liquid in cavity of body, caused by cancer, as active substance containing covalent conjugate of interferon-beta with polyethylene glycol.
EFFECT: invention provides effective treatment and removal of liquid from body cavity by systemic administration as well as by local administration.
9 cl, 6 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES FOR ADMINISTERING BIOLOGICALLY ACTIVE COMPOUNDS | 2009 |
|
RU2567667C2 |
| CANCER IMMUNOREHABILITAITON MODE | 2008 |
|
RU2377994C1 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING INTERFERON-ALPHA CONJUGATE | 2012 |
|
RU2622077C2 |
| AGENT FOR REGULATION OF ENDOGENOUS PRODUCTION OF CYTOKINE AND HEMOPOIETIC FACTOR (VARIANTS) AND METHOD OF ITS USING | 1996 |
|
RU2153351C2 |
| PEGYLATED RECOMBINANT CONSENSUS INTERFERON VERSION CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 2011 |
|
RU2575796C9 |
| METHOD FOR DETECTING AND TREATING CANCER | 1995 |
|
RU2161042C2 |
| THERAPEUTIC APPLICATION OF NEW PHARMACEUTICAL PREPARATIONS CONTAINING ANTINEOPLASTIC DRUGS, ASSOCIATED WITH HYALURONIC ACID, IN TREATING NEOPLASMS | 2009 |
|
RU2581972C2 |
| NEW METHOD FOR PRODUCTION OF LIPOPLEX FOR LOCAL INTRODUCTION AND ANTI-TUMOR MEDICATION THAT USES SUCH LIPOPLEX | 2015 |
|
RU2671857C1 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
| COMBINATION THERAPY WITH SEMAFORIN 4D (SEMA4D) BLOCKING AND DC1 THERAPY | 2020 |
|
RU2801828C2 |
